About: Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2000 (uk) 2000 സപ്തംബര്‍ 1 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം (ml) article scientifique publié en 2000 (fr) im September 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 2000 (ast) scientific article published on 01 September 2000 (en)
publication date	wds:Q60611912-62AC546E-9DB3-457E-AB9B-8656B9C86E57 wds:Q60611912-F43D1211-8E78-45A0-9D95-D14651B6564C
publication date	2000-09-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q60611912-018EF591-98E8-40B5-8D0C-9BCD2A6211B9 wds:Q60611912-2C0704DB-999D-463C-9FCB-2012400D3D96 wds:Q60611912-318BABF8-BB0A-447B-92E5-143B1DE524AE wds:Q60611912-61CD8C80-7275-404D-B0B0-23F156C08378 wds:Q60611912-9BBA5921-B558-4A84-BEFE-7254A1BF4096 wds:Q60611912-CD2A4AD3-8E59-461A-B80B-3B21A28A2662
author name string	Barbieri M Diana Conte Camerino Domenico Tricarico Camerino DC Tricarico D Mariagrazia Barbieri
rdfs:label	Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (en) Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (nl)
skos:prefLabel	Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (en) Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (nl)
name	Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (en) Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (nl)
title	wds:Q60611912-6183FAB8-CBA9-4C4A-A149-37879D859626 wds:Q60611912-BB124027-BEC4-4524-814B-8C2C77B2416E
title	Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (en) Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (en)
page(s)	wds:Q60611912-D1BE6972-5F6D-4789-8517-C929A23892D8
page(s)	304-312
instance of	wds:Q60611912-94977D78-D008-4F44-8635-98F3C9FD2481
instance of	scholarly article
main subject	wds:Q60611912-73A8A456-5AD0-4E11-AEE4-C1463D9FFBB4 wds:Q60611912-8333BB04-D6B0-40B6-A8CF-BF401451E9C4
main subject	hypokalemic periodic paralysis wd:Q413690
PubMed ID	wds:Q60611912-6C0EF348-F72E-411D-A46D-A3E05A895A55
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10976636
PubMed ID	10976636
published in	wds:Q60611912-53F2765D-48E9-4B12-BABE-A6CF39089276
published in	Annals of Neurology
issue	wds:Q60611912-A5D77D27-DA56-4561-BA28-2D63C4BAB1B2
volume	wds:Q60611912-D72BF599-FA21-44AB-94F6-C854015AFF24
issue	3
volume	48
DOI	wds:Q60611912-B6CF2E7E-ADC7-4652-8E00-D69C6A893331
DOI	http://dx.doi.org/10.1002/1531-8249(200009)48:3%3C304::AID-ANA4%3E3.0.CO;2-A
DOI	10.1002/1531-8249(200009)48:3<304::AID-ANA4>3.0.CO;2-A
skos:altLabel	Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (en) Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis (nl)
is owl:sameAs of	Acetazolamide opens the muscular K Ca 2+ channel: A novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q60611912
is cites work of	Periodic paralysis Treatment for periodic paralysis Sodium channelopathies of skeletal muscle result from gain or loss of function Emerging role of calcium-activated potassium channel in the regulation of cell viability following potassium ions challenge in HEK293 cells and pharmacological modulation Autosomal dominant nocturnal frontal lobe epilepsy--a critical overview Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia Extracellular H+ induces Ca2+ signals in respiratory chemoreceptors of zebrafish. K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies Splicing of the rSlo gene affects the molecular composition and drug response of Ca2+-activated K+ channels in skeletal muscle Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats. Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder Channelopathies of skeletal muscle excitability Differential cerebellar GABAA receptor expression in mice with mutations in CaV2.1 (P/Q-type) calcium channels Periodic paralysis: understanding channelopathies Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? ClC-1 chloride channels: state-of-the-art research and future challenges. Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes Topiramate hyperpolarizes and modulates the slow poststimulus AHP of rat olfactory cortical neurones in vitro. State of the art in hereditary muscle channelopathies Periodic paralysis Treatment in myotonia and periodic paralysis Acetazolamide in vestibular migraine prophylaxis: a retrospective study A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G) Rhabdomyolysis following severe hypokalemia caused by familial hypokalemic periodic paralysis Inhibition of oxygen consumption in skeletal muscle-derived mitochondria by pinacidil, diazoxide, and glibenclamide, but not by 5-hydroxydecanoate Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options Electrophysiology and molecular pharmacology of muscle channelopathies. The noncarbonic anhydrase inhibiting acetazolamide analog N-methylacetazolamide reduces the hypercapnic, but not hypoxic, ventilatory response Sporadic hemiplegic migraine Ion channels in muscle and cardiac hereditary diseases: from gene dysfunction to pharmacological therapy
is cites work of	wds:Q24247009-9E8A8D87-6E15-4318-A594-450C209110A1 wds:Q28586378-781C746D-31B6-4772-BDA5-C11AA3BB95A1 wds:Q37383463-E1CFC6E3-D051-4F1D-8751-BEF5D774564D wds:Q35991521-FF40CD5D-E3A5-49C1-87AE-4C4DD7304362 wds:Q42610360-D2F73FD7-4CB5-43B1-9066-367A334CD514 wds:Q82029865-6FFE9A6E-6A92-443A-852B-865A6545ECF9 wds:Q35843236-7B838ADB-8F1C-4B30-BA3C-BE3E423292F7 wds:Q35865848-13BC1E52-E3A2-498A-962C-04B29EF05E77 wds:Q34015907-A1156086-C990-47F3-9401-90DC60C61EF4 wds:Q41789251-D58BD1DA-0A25-4AC7-B2D9-CC7B98C1661F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software